Shots:

• Under the terms of collaboration, Iktos will use its de novo ligand & structure-based generative modeling technologies & software Makya, planning tool Spaya to speed up the identification of pre-clinical candidates & identify novel chemical matter with appropriate properties
• Iktos has expanded its R&D efforts in the development of an AI technology for retrosynthesis. AI-based retrosynthesis analysis & Spaya enables the systematic exploration & prioritization of synthetic routes for the desired molecule in min.
• Iktos’s AI technology brings new insights & directions into the drug discovery process based on data-driven technology. This technology generates virtual new molecules having all of the characteristics of a therapeutic molecule

Ref: Bussinesswire | Image: Iktos